E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy.

Treatment-free remission (TFR) is a new therapy goal for patients with chronic phase chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs), with approximately 40% sustaining deep molecular responses after stopping treatment.[1][1]–[3][2] However, it is difficult to predict